SCHEMBL4363876

SCHEMBL4363876

CN(Cc1ccccc1)c1ccc(SNC(=O)NC(=O)c2cc3ccccc3o2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.47
OPRM1 P35372 1/20 0.47
OPRK1 P41145 1/20 0.47
TMEM97 Q5BJF2 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
ALDH1A1 P00352 6/20 0.47
HPGD P15428 2/20 0.47
RAB9A P51151 5/20 0.44
KMT2A Q03164 4/20 0.44
NPC1 O15118 4/20 0.44
MEN1 O00255 3/20 0.44
TP53 P04637 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
LMNA P02545 3/20 0.40
CLK1 P49759 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364790 0.86 HDAC3 (0.45) ACKR3OPRM1OPRK1TMEM97SIGMAR1
SCHEMBL4363882 0.80 MAPT (0.59) ACKR3OPRM1OPRK1TMEM97SIGMAR1
SCHEMBL3425368 0.79 ALDH1A1 (0.39) ALDH1A1RAB9AKMT2ANPC1MEN1
SCHEMBL3634482 0.77 SMN1; SMN2 (0.51) ALDH1A1HPGDRAB9AKMT2ANPC1
SCHEMBL4366956 0.75 SMN1; SMN2 (0.48) ALDH1A1HPGDRAB9AKMT2ANPC1
SCHEMBL4370668 0.74 SMN1; SMN2 (0.50) ALDH1A1HPGDRAB9AKMT2ANPC1
SCHEMBL4538068 0.74 SMN1; SMN2 (0.49) ALDH1A1HPGDRAB9ANPC1TP53
SCHEMBL4361546 0.73 HPGD (0.49) ALDH1A1HPGDRAB9AKMT2ANPC1
SCHEMBL4360383 0.72 SMN1; SMN2 (0.47) ALDH1A1HPGDRAB9AKMT2ANPC1
SCHEMBL4362127 0.71 RAB9A (0.42) ALDH1A1HPGDRAB9AKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US claimed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US claimed
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2004-07-15 US claimed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, TPMT ACKR3 862/4885OPRM1 1742/4885OPRK1 2395/4885
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 ACKR3 707/4885OPRM1 1861/4885OPRK1 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.